Research ExplorerPublicationsStaged surgery with neoadjuvant 90Y-DOTATOC therapy for down...

Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor.

Standard

Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor. / Stöltzing, Oliver; Loss, Martin; Huber, Elisabeth; Gross, Volker; Eilles, Christoph; Mueller-Brand, Jan; Schlitt, Hans J.

In: LANGENBECK ARCH SURG, Vol. 395, No. 2, 2, 2010, p. 185-192.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Stöltzing, O, Loss, M, Huber, E, Gross, V, Eilles, C, Mueller-Brand, J & Schlitt, HJ 2010, 'Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor.', LANGENBECK ARCH SURG, vol. 395, no. 2, 2, pp. 185-192. <http://www.ncbi.nlm.nih.gov/pubmed/19506898?dopt=Citation>

APA

Stöltzing, O., Loss, M., Huber, E., Gross, V., Eilles, C., Mueller-Brand, J., & Schlitt, H. J. (2010). Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor. LANGENBECK ARCH SURG, 395(2), 185-192. [2]. http://www.ncbi.nlm.nih.gov/pubmed/19506898?dopt=Citation

Vancouver

Stöltzing O, Loss M, Huber E, Gross V, Eilles C, Mueller-Brand J et al. Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor. LANGENBECK ARCH SURG. 2010;395(2):185-192. 2.

Bibtex

@article{1e3bcfb1ba184160a5460ffd042943ae,
title = "Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor.",
abstract = "Treatment with DOTA-d-Phe(1)-Tyr(3)-octreotide (DOTATOC), labeled with beta-emitting radioisotope yttrium-90 ((90)Y-DOTATOC), has successfully been used for the palliative treatment of patients with advanced somatostatin receptor-expressing neuroendocrine tumors (NETs). However, controversy persists as to whether patients with metastatic NETs of the pancreas should undergo radical (salvage) surgery or receive palliative therapy. We proposed that (90)Y-DOTATOC could be used in a neoadjuvant intention for improving therapy of hepatic NET metastases.",
author = "Oliver St{\"o}ltzing and Martin Loss and Elisabeth Huber and Volker Gross and Christoph Eilles and Jan Mueller-Brand and Schlitt, {Hans J}",
year = "2010",
language = "Deutsch",
volume = "395",
pages = "185--192",
journal = "LANGENBECK ARCH SURG",
issn = "1435-2443",
publisher = "Springer",
number = "2",

}

RIS

TY - JOUR

T1 - Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor.

AU - Stöltzing, Oliver

AU - Loss, Martin

AU - Huber, Elisabeth

AU - Gross, Volker

AU - Eilles, Christoph

AU - Mueller-Brand, Jan

AU - Schlitt, Hans J

PY - 2010

Y1 - 2010

N2 - Treatment with DOTA-d-Phe(1)-Tyr(3)-octreotide (DOTATOC), labeled with beta-emitting radioisotope yttrium-90 ((90)Y-DOTATOC), has successfully been used for the palliative treatment of patients with advanced somatostatin receptor-expressing neuroendocrine tumors (NETs). However, controversy persists as to whether patients with metastatic NETs of the pancreas should undergo radical (salvage) surgery or receive palliative therapy. We proposed that (90)Y-DOTATOC could be used in a neoadjuvant intention for improving therapy of hepatic NET metastases.

AB - Treatment with DOTA-d-Phe(1)-Tyr(3)-octreotide (DOTATOC), labeled with beta-emitting radioisotope yttrium-90 ((90)Y-DOTATOC), has successfully been used for the palliative treatment of patients with advanced somatostatin receptor-expressing neuroendocrine tumors (NETs). However, controversy persists as to whether patients with metastatic NETs of the pancreas should undergo radical (salvage) surgery or receive palliative therapy. We proposed that (90)Y-DOTATOC could be used in a neoadjuvant intention for improving therapy of hepatic NET metastases.

M3 - SCORING: Zeitschriftenaufsatz

VL - 395

SP - 185

EP - 192

JO - LANGENBECK ARCH SURG

JF - LANGENBECK ARCH SURG

SN - 1435-2443

IS - 2

M1 - 2

ER -